To evaluate the efficacy of entecavir (ETV) among chronic hepatitis B (CHB) nucleos(t)ide-naïve and -experienced patients in clinical practice. Materials and methods: In this retrospective study 85 CHB patients who had been receiving ETV and who attended our clinic since 2007 were included. Fifty patients were nucleos(t)ide analogue (NA)-naïve. Factors including sex, positive HBeAg, baseline HBV DNA level, baseline alanine aminotransferase level, and prior lamivudine (LAM) resistance were evaluated in terms of their predictive role in treatment response, which was defined as a serum HBV DNA decrease of
BİÇER, KADİR ÇAĞATAY; ARI, ALPAY; GENÇ, VECDİ EVREN; CAYMAZ, SİBEL ÖZSU; AVCI, MELTEM; and BAL, FATMA
"Efficacy of entecavir treatment among chronic hepatitis B nucleos(t)ide-naïve and -experienced patients,"
Turkish Journal of Medical Sciences: Vol. 45:
1, Article 16.
Available at: https://journals.tubitak.gov.tr/medical/vol45/iss1/16